Systematic risk identification and assessment using a new risk map in pharmaceutical R&D
Journal
Drug Discovery Today
ISSN
1359-6446
Type
journal article
Date Issued
2021
Author(s)
Abstract (De)
Delivering transformative therapies to patients while maintaining growth in the pharmaceutical
industry requires an efficient use of research and development (R&D) resources and technologies to
develop high-impact new molecular entities (NMEs). However, increasing global R&D competition in
the pharmaceutical industry, growing impact of generics and biosimilars, more stringent regulatory
requirements, as well as cost-constrained reimbursement frameworks challenge current business
models of leading pharmaceutical companies. Big data-based analytics and artificial intelligence (AI)
approaches have disrupted various industries and are having an increasing impact in the biopharma�ceutical industry, with the promise to improve and accelerate biopharmaceutical R&D processes. Here,
we systematically analyze, identify, assess, and categorize key risks across the drug discovery and
development value chain using a new risk map approach, providing a comprehensive risk–reward
analysis for pharmaceutical R&D.
industry requires an efficient use of research and development (R&D) resources and technologies to
develop high-impact new molecular entities (NMEs). However, increasing global R&D competition in
the pharmaceutical industry, growing impact of generics and biosimilars, more stringent regulatory
requirements, as well as cost-constrained reimbursement frameworks challenge current business
models of leading pharmaceutical companies. Big data-based analytics and artificial intelligence (AI)
approaches have disrupted various industries and are having an increasing impact in the biopharma�ceutical industry, with the promise to improve and accelerate biopharmaceutical R&D processes. Here,
we systematically analyze, identify, assess, and categorize key risks across the drug discovery and
development value chain using a new risk map approach, providing a comprehensive risk–reward
analysis for pharmaceutical R&D.
Language
English
HSG Classification
contribution to scientific community
HSG Profile Area
SoM - Business Innovation
Refereed
Yes
Publisher
Elsevier Science
Subject(s)
Division(s)
Eprints ID
263555